Filter
96
Filtered Results: 96
Text search:
Drug
Administration
and
Control
Authority
of
Ethiopia
,
et
al.
Featured
Recommendations
12
New Publications
33
Language
Document type
No document type
51
Studies & Reports
23
Guidelines
12
Manuals
5
Strategic & Response Plan
4
Training Material
1
Countries / Regions
Ethiopia
28
Kenya
7
Global
4
Congo, Democratic Republic of
3
Ghana
3
Zambia
3
Africa
3
Uganda
2
Jordan
2
Tanzania
2
South Africa
2
Bangladesh
2
Malawi
2
Sudan
2
Iran
2
Liberia
1
Nigeria
1
Morocco
1
Saudi Arabia
1
Philippines
1
Somalia
1
Pakistan
1
Iraq
1
Lebanon
1
Syria
1
Thailand
1
Rwanda
1
Central African Republic
1
Namibia
1
Greece
1
Mexico
1
Myanmar / Burma
1
Middle East and North Africa
1
Venezuela
1
Albania
1
Georgia
1
Tunisia
1
Authors & Publishers
Publication Years
Category
Countries
46
Public Health
10
Clinical Guidelines
9
Key Resources
8
Capacity Building
3
Pharmacy & Technologies
3
Women & Child Health
2
Toolboxes
Pharmacy
11
AMR
10
NTDs
8
HIV
6
TB
6
Rapid Response
3
Caregiver
3
Polio
2
Mental Health
2
Global Health Education
2
COVID-19
2
Planetary Health
2
NCDs
2
Cholera
1
Conflict
1
Natural Hazards
1
STGs are designed to assist health care professionals in making decisions about appropriate, effective patient care. However, health managers often have trouble setting and meeting the high standards required ... modern, developed health care systems. With stakeholders expressing concern over issues such as strength of evidence, transparency, conflicts of interest, and effective implementation, it is clear that many health care professionals need further guidance in developing and making use of STGs.
This manual guides health professionals through the process of establishing and implementing STGs, placing special emphasis on the low- and middle-income country (LMIC) context. By including tools, templates, and success stories as well as hyperlinks to useful resources, the manual helps health practitioners understand not only important concepts of treatment guidelines, but also how they can best be used in practice.
International Journal of Infectious Diseases 32 (2015) 170–178
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ß 2014 The Authors. Published by Elsevier Ltd on behalf of Internationa...
A manual for programme managers.
БОРЬБА С ТУБЕРКУЛЕЗОМ В ТЮРЬМАХ
Руководство для руководителей программ
The classification of digital health interventions (DHIs) categorizes the different ways in which digital and mobile technologies are being used to support health system needs. Historically, the di...
The purpose of the landscape analysis is ultimately to facilitate improved engagement of private providers, thereby contributing to universal access to quality ... affordable TB care and the end of the TB epidemic. It focuses on the role of private for-profit providers and on specific challenges and experiences in engaging them for TB prevention and care.
This policy brief aims to provide a review of the current progress on implementing the Kenya national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further prog...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect ... the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect ... the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the vari...
Le présent document de travail a été conçu pour offrir des conseils pratiqueset des suggestions sur la manièred’établir et de maintenir la collaboration multisectorielle nécessaire pour élaborer ... mettre en œuvre les plans d’action nationaux (PAN) de lutte contre la RAM. Il s’adresse à tous ceux qui ont pourresponsabilité de combattre la RAM au niveau national. S’appuyant à la fois sur la littérature publiée et sur l’expérience pratique de quatre «pays focaux» (Éthiopie, Kenya, Philippines et Thaïlande), ce documentrésume les enseignements tirés et les derniers points de vuesur la collaboration multisectorielle en vue d’une action efficace contre la RAM.
Robust clinical research capacity in low- and middle-income countries is key to stemming the spread of epidemics, according to a new report from the International Vaccines Task Force (IVTF). The rep...
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that ...
This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are respo...
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad sp...
